Company: MDCXW
Filing Date: 2025-04-25
Form Type: DRS
Source: 0001062993-25-007956
Chunk: 10

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-25
Form: DRS
Chunk 10
---
MA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

Our Strengths

Our key competitive strengths include:

•A senior management team, led by Dr. Raza Bokhari, that has deep experience in medicine and pharmaceutical science as well as a proven track record in business development and entrepreneurship.

•Successful completion of a Phase 1 study of the Product.

•Potential to treat a range of other common non-melanoma skin cancers as well as pre-cancerous lesions.

Summary Risk Factors

Investing in our securities involves risk. Our ability to execute our strategy is also subject to certain risks. The risks described in "Risk Factors" in this prospectus may cause us to not realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the more significant risks include the following:

•our financial results, including our ability to generate earnings and achieve and sustain profitability (as of December 31, 2024, we had an accumulated deficit of approximately $28.9 million), may vary significantly from forecasts and from period to period;

•the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates

•our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates, our ability to develop, manage and maintain our direct sales and marketing organizations;

•our ability to continue as a going concern and if we are unable to obtain additional financing from outside sources and/or eventually generate enough revenues, we may be forced to curtail or discontinue our operations;

•our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing;

•market risks regarding consolidation in the healthcare industry;

•the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines;

•our ability to adequately protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

•the fact that product quality issues or product defects may harm our business, any product liability claims; and

•the regulatory, legal and certain operating risks that our operations subject us to.

Please see "Risk Factors" for a discussion of these and other factors you should consider before making an investment in our securities.

<div align='center'>2</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSU